Evidence map›Paper›PMID 39900779›Full record

ReviewOrthopadie (Heidelberg, Germany)2025

[The weight-loss injection : An orthopaedic overview].

Saif Al Basri, Wiebke K Fenske

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Orthopadie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Saif Al BasriAllgemeine Innere Medizin, Endokrinologie und Diabetologie, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH, Bürkle-de-la-Camp-Platz 1, 44789, Bochum, Deutschland. saif.albasri@ruhr-uni-bochum.de.
Wiebke K FenskeAllgemeine Innere Medizin, Endokrinologie und Diabetologie, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH, Bürkle-de-la-Camp-Platz 1, 44789, Bochum, Deutschland. Wiebke.Fenske@bergmannsheil.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increasing prevalence of obesity represents a significant and growing challenge in orthopaedic surgery. This is particularly true for patients with morbid obesity, who have a significantly increased risk of postoperative complications. The newer incretin-based therapies (such as semaglutide and tirzepatide), these so-called "weight loss injections", offer promising potential for preoperative weight reduction and minimisation of peri- and postoperative complications. STUDY SITUATION: However, the evidence regarding their influence on postoperative outcomes is inconsistent. Retrospective studies suggest that rapid weight loss immediately prior to orthopaedic surgery may increase the risk of complications, including septic shock and revision surgery. Meta-analyses, on the other hand, indicate potential protective effects in surgical outcomes with prior long-term weight reduction.

conclusionThere are currently no sufficiently qualitative studies on the safety and efficacy of these new drugs in the orthopaedic surgery sector. An individualised and multidisciplinary approach, therefore, remains relevant in order to achieve an optimal surgical outcome for the individual patient.

Indexed as

Anti-Obesity AgentsGlucagon-Like PeptidesIncretinsObesityObesity, MorbidOrthopedic ProceduresPostoperative ComplicationsWeight LossGlucagon-Like Peptide 1HumansSemaglutideAnti-Obesity AgentsGlucagon-Like Peptide 1Glucagon-Like PeptidesIncretinsSemaglutideBariatric surgeryGLP-1-RAIncretinsMorbid obesitySemaglutideTirzepatideTreatment outcome

Identifiers

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.